![]() |
|
|
Vol. 297, Issue 3, 991-1000, June 2001
Department of Pharmaceutical Sciences, College of Pharmacy,
University of Nebraska Medical Center, Omaha, Nebraska (H.S., W.F.E.);
and Drug Delivery and Kinetics Resource, Division of Bioengineering and
Physical Science, National Institutes of Health, Bethesda, Maryland
(P.M.B.)
Intracerebral microdialysis probe recovery (extraction fraction) may be
influenced by several mass transport processes in the brain, including
efflux and uptake exchange between brain and blood. Therefore, changes
in probe recovery under various experimental conditions can be useful
to characterize fundamental drug transport processes. Accordingly, the
effect of inhibiting transport on probe recovery was investigated for
two capillary efflux transporters with potentially different membrane
localization and transport mechanisms, P-glycoprotein and an organic
anion transporter. Fluorescein/probenecid and quinidine/LY-335979 were chosen as the substrate/inhibitor combinations for organic anion transport and P-glycoprotein-medicated transport, respectively. Probenecid decreased the probe recovery of fluorescein in frontal cortex, from 0.21 ± 0.017 to 0.17 ± 0.020 (p < 0.01). Quantitative microdialysis calculations indicated that
probenecid treatment reduced the total brain elimination rate constant
by 3-fold from 0.37 to 0.12 (ml/min · ml of extracellular
fluid). In contrast, the microdialysis recovery of quinidine, delivered
locally to the brain via the probe perfusate, was not sensitive to
P-glycoprotein inhibition by systemically administered LY-335979, a
potent and specific inhibitor of P-glycoprotein. Recovery of
difluorofluorescein, an analog of fluorescein, was also decreased by
probenecid in the frontal cortex but not in the ventricle cerebrospinal
fluid. These experimental observations are in qualitative agreement
with microdialysis theory incorporating mathematical models of
transporter kinetics. These studies suggest that only in certain
circumstances will efflux inhibition at the blood-brain barrier and
blood-cerebrospinal fluid barrier influence the microdialysis probe
recovery, and this may depend upon the substrate and inhibitor examined
and their routes of administration, the localization and mechanism of
the membrane transporter, as well as the microenvironment surrounding the probe.
This article has been cited by other articles:
![]() |
H. Dai, Y. Chen, and W. F. Elmquist Distribution of the Novel Antifolate Pemetrexed to the Brain J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 222 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Benjamin, F. H. Hochberg, E. Fox, P. M. Bungay, W. F. Elmquist, C. F. Stewart, J. M. Gallo, J. M. Collins, R. P. Pelletier, J. F. de Groot, et al. Review of microdialysis in brain tumors, from concept to application: First Annual Carolyn Frye-Halloran Symposium Neuro-oncol, January 1, 2004; 6(1): 65 - 74. [Abstract] [PDF] |
||||
![]() |
G. F. Clough, P. Boutsiouki, M. K. Church, and C. C. Michel Effects of Blood Flow on the in Vivo Recovery of a Small Diffusible Molecule by Microdialysis in Human Skin J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 681 - 686. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. B. Newman, S. Rattigan, and M. G. Clark Nutritive blood flow improves interstitial glucose and lactate exchange in perfused rat hindlimb Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H186 - H192. [Abstract] [Full Text] [PDF] |
||||